

DAFTAR PUSTAKA

- Adhvaryu, M.R., Reddy, N.M., Vakharia, B.C. 2008. Prevention of hepatotoxicity due to anti tuberculosis treatment: A novel integrative approach. *World Journal of Gastroenterology*. Vol. 14, 4753-4762.
- Alvarez-Uria, G., Midde, M., Pakam, R., Kumar, P.N. 2013. *Diagnostic and Prognostic Value of Serum Albumin for Tuberculosis in HIV Infected Patient Eligible for Antiretroviral Therapy : Data from an HIV Cohort Study in India*.
- Arbex, M. A., Varella, M. D. C. L., Siqueira, H. R. D., & Mello, F. A. F. D. 2010. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations-part 1: first-line drugs. *Jornal Brasileiro de Pneumologia*, **36**(5), 626-640.
- Azhari, Mohammad Reza. 2015. Hubungan Antara Pengobatan Tuberculosis Pada Pasien Tuberculosis dengan Gizi Kurang terhadap Kejadian Hepatitis Imbas Obat di Balai Besar Kesehatan Paru Masyarakat Surakarta. Universitas Muhammadiyah Surakarta.
- Baciewicz, A. M., & Self, T. H. 1984. Rifampin drug interactions. *Archives of internal medicine*, **144**(8), 1667-1671.
- Bharadwaj S, Ginoya S, Tandon P, Gohel TD, Guirguis J, Vallabh H, et al. Malnutrition: Laboratory markers vs nutritional assessment. *Gastroenterology report* 2016; **4**(4): 272-280.
- Bhargava A, Chatterjee M, Jain Y, Chatterjee B, Kataria A, Bhargava M, et al. *Nutritional status of adult patients with pulmonary tuberculosis in rural central india and its association with mortality. PloS one* 2013; **8**(10).
- Boshoff, H. I., Mizrahi, V., & Barry, C. E. 2002. Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. *Journal of bacteriology*, **184** (8), 2167-2172.
- Brunton, L., Chabner, B., dan Knollman, B. 2011. *Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th Edition*. McGraw-Hill Companies Inc.
- Carroll M., Lee M., Cai Y., Hallahan CW., Shaw PA., Min JH et al. 2012. Frequency of adverse reactions too first- and second-line

antituberculosis chemotherapy in a Korean cohort. *Int. J. Tuberc. Lung Dis: Off. J. Int. Union against Tuberc. And Lungs Dis*: 16(7):961-6. Epub 2012/05/16.11).

David, S., Hamilton, J.P. 2010. *Drug Induced Liver Injury*. US Gastroenterol Hepatol Rev. 6: 73-80.

Dipiro, J.T., Talbert, R.L., Yee, C.C., Matzke, G.R., Wells, B.G., dan Posey, M.L. 2011. *Pharmacotherapy: A Pathophysiologic Approach 8th Edition*. McGraw-Hill Companies, Inc.

Drugbank.. <https://www.drugbank.ca/>. Online. Februari. 2020

Farrell, G.C. 1994; Drug-induced acute hepatitisIn: Drug-induced liver disease Farrell GG (Ed.). *Churchill Livingstone, Edinburgh, UK*. 247–299

Fishbach, F.T., Dunning,. M.B. 2009. *Manual of Laboratory and Diagnostic Tests, 8th ed. Philadelphia*: Lippicott Williams and Wilkins.

Gounden V, Vashisht R, and Jialal I., 2020., *Hypoalbuminemia., StatPearls Publishing: Treasure Island (FL)*. p. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526080/>.

Heym, B., Alzari, P. M., Honore, N., & Cole, S. T. 1995. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. *Molecular microbiology*, **15**(2), 235-245.

Huang, X.J., Choi, Y.K., Im, H.S., Yarimaga, O., Yoon, E., & Kim, H.S. 2006. Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection techniques. *Sensors*, **6**(7), 756-782.

Indah, M. 2018. Tuberkulosis. *InfoDATIN : Pusat Data dan Informasi Kementerian Kesehatan RI*

Indonesia, P. D. P. 2011. Tuberkulosis: pedoman diagnosis dan penatalaksanaan di Indonesia. *Jakarta: PDPI*, 20-30.

- Jeong, I., Park, J.S., Cho, Y.J., Yoon, H. Song, J. Lee, C.T., Lee, J.H. 2014. Drug Induced Hepatotoxicity of Anti-tuberculosis Drug and Their Serum Levels. *Journal Korean Sci.* 30: 67-172.
- Karyadi E, Schultink W, Nelwan RH, Gross R, Amin Z, Dolmans WM, et al., 2000., Poor micronutrient status of active pulmonary tuberculosis patients in indonesia. *The Journal of nutrition*; **130**(12): 2953-2958.
- Katzung, B.G. 2018. *Basic & Clinical Pharmacology 14th Edition*. McGraw Hill Education. New York.
- Kee, J.L. 2007. *Pedoman Pemeriksaan Laboratorium dan Diagnostik, Edisi 6*. Jakarta: EGC.
- Keller U., 2019., Nutritional laboratory markers in malnutrition. *Journal of clinical medicine* 2019; **8**(6): 775.
- Kementerian Kesehatan RI. 2014. *Pedoman Nasional Pengendalian Tuberkulosis*. Jakarta.
- Kementerian Kesehatan RI. 2019. *Tabel Batas Ambang Indeks Massa Tubuh (IMT)*. Jakarta.
- Khalili H, Dashti-Khavidaki S, Rasoolinejad M, Rezaie L, and Etminani M., 2009., *Antituberculosis drugs related hepatotoxicity; incidence, risk factors, pattern of changes in liver enzymes and outcome*. *DARU*; **17**(3): 163-167.
- Lai H-H, Lai Y-J, and Yen Y-F., 2017., Association of body mass index with timing of death during tuberculosis treatment. *PloS one*; **12**(1).
- Lopa, AT., Rusli, B., Arif, M.,Hardjoeno. 2007. Analisis Kadar Albumin Serum dengan Rasio De Ritis pada Penderita Hepatitis B. *Indonesian Journal of Clinical Pathology and Medical Laboratory*; **13**(2): 60-2.
- Makhlouf H.A, Helmy A, Fawzy E, El-Attar M, Rashed H.A.G., 2008. *A Prospective Study of Antituberculosis Drug-Induced Hepatotoxicity in An Area Endemic for Liver Disease*. *Hepatology International* **2** (3): 353-360.
- Martindale, W., & Parfitt, K. 1999. *Martindale: the complete drug reference*. London: Pharmaceutical press.

- Medscape. 2018. Drug Interaction Checker, (Online). (<http://www.reference.medscape.com/drug-interactionchecker>) diakses Mei 2021
- Murray, R.K., Granner, D.K., Rodwell, V.W. 2009. *Biokimia Harper*. Jakarta : EGC.
- Ngo, S. C., Zimhony, O., Chung, W. J., Sayahi, H., Jacobs, W. R., & Welch, J. T. 2007. Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs. *Antimicrobial agents and chemotherapy*, **51**(7), 2430-2435
- Njoku, D.B. 2014. Drug-Induced Hepatotoxicity: Metabolic, Genetic and Immunological Basis. *International Journal of Molecular Sciences*. Vol. 15, 6990-7003.
- Nugroho, Dwi Atmoko. 2012. Hubungan Antara Status Gizi dengan Efek Samping Obat Antituberkulosis pada Pasien Dewasa di BKPM Pati tahun 2011. Universitas Muhammadiyah Surakarta.
- Peloquin, C. A. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. *Drugs*, **62**(15), 2169-2183.
- Perhimpunan Dokter Paru Indonesia. 2006. Tuberkulosis: *Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia.
- Piot, P. 2008. *Nutrition and health in developing countries*. Springer Science & Business Media.
- Prihatni, D., Parwati, I., Sjahid, I., & Rita, C. 2018. Efek Hepatotoksik Anti Tuberkulosis Terhadap Kadar Aspartate Aminotransferase dan Alanine Aminotransferase Serum Penderita Tuberkulosis Paru. *Indonesian journal of clinical pathology and medical laboratory*. **12**(1) : 1-5.
- Priyantomo, Edo Putra. 2014. Gambaran Indeks Massa Tubuh (IMT) pada Pasien Tuberkulosis Paru Aktif yang Menjalani Terapi Obat Anti Tuberkulosis (OAT) di Unit Pengobatan Penyakit Paru Paru (UP4) Pontianak.

- Putri W.A, Munir S.M, dan Christianto E. 2016. *Gambaran Status Gizi pada Pasien Tuberkulosis Paru (TB Paru) yang Menjalani Rawat Inap di RSUD Arifin Achmad Pekanbaru*. JOM FK 3 (2).
- Ramappa, V., Aithal, G.P. 2013. Hepatotoxicity Related to Anti-tuberculosis Drugs : Mechanisms and Management. J. Clin. Exp. Hepatol. **3**(1) : 37-49.
- Rangel M.A, Pais I.P, Duarte R, dan Carvalho I. 2017. *Antituberculosis Drug-Induced Liver Injury with Autoimmune Features: Facing Diagnostic and Treatment Challenges*. Hindawi Case Reports in Pediatrics Volume 2017 Article ID 5741896.
- Rosida, Azma. 2016. Pemeriksaan Laboratorium Penyakit Hati. Berkala Kedokteran Vol.12. 1 : 123-131.
- Schmitz, G., Hans L., Heidrich M. 2009. *Farmakologi dan Toksikologi Edisi 3*, diterjemahkan oleh Joseph & Amalia Hanif : 553-563. Penerbit Buku Kedokteran.
- Self, T.H., Chrisman, C.R., Baciewicz, A.M., Bronze, M.S. 1999. Isoniazid drug and food interactions. The American journal of the medical sciences, **317**(5), 304-311.
- Sherlock,S., Dooley,J. 2002. *Diseases of the Liver and Biliary System*. United State of America: Blackwell Publishing.
- Shu C, Lee C, Lee M, Wang JY, Yu C, and Lee L., 2013., Hepatotoxicity due to first-line antituberculosis drugs: A five-year experience in a taiwan medical centre. *The International Journal of Tuberculosis and Lung Disease*; **17**(7): 934-939
- Sidabutar B, Soedibyso S, and Tumbelaka A., 2004 *Nutritional status of under-five pulmonary tuberculosis patients before and after six-month therapy*. *Paediatrica Indonesiana*; **44**(1): 21-4.
- Soeters, P.B., Wolfe, R.R., Shenkin, A.H. 2018. *Hypoalbuminemia : Pathogenesis and Clinical Significance*. **43** (2) : 181-193.
- Suryaatmadja M. 2009. *Pemeriksaan Laboratorium Uji Fungsi Liver*. Bulletin ABC. 11: 2-8.
- Sutedjo. 2006. *Mengenal Penyakit Melalui Hasil Pemeriksaan Laboratorium*. Yogyakarta : Amara Books.

- Tostmann, A., Boeree, M.J., Aarnoutse, R.E., Wiel C M de Lange, van der Ven, A.J.A.M., Dekhuijzen, R. 2008. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. *J. Gastroenterol. Hepatol.* **23** (2) : 192-202
- Tungadi, Novia Wira. 2017. Hubungan Nilai Protrombine Time dan Albumin dengan Staging Pasien Sirosis Hepatis di RSUP Dr. Wahidin Sudirohusodo Makassar periode Januari-Desember 2016. Fakultas Kedokteran Universitas Hasanuddin. Skripsi.
- Wahyudi, A.D., Soedarsono. 2015. Farmakogenomik Hepatotoksisitas Obat Antituberkulosis. *Journal Respirasi.* Vol.1. No. 3: 103-108
- WHO. 2018. *Global Tuberculosis Report.*
- Wojtowicz., E.J., Elzbieta B., Violetta S. 2007. *Testosterone Estradiol Progesterone and Sex Hormone Binding Globuline (SHBG) Blood Serum Levels in Men Acute Viral Hepatitis A or B.* Med Sci Monit. **3**(5): 686-691.
- World Health Organization. 2017. *Guidelines for treatment of drug-susceptible tuberculosis and patient care.* Geneva : World Health Organization
- Yen Y-F, Chuang P-H, Yen M-Y, Lin S-Y, Chuang P, Yuan M-J, et al., 2016., Association of body mass index with tuberculosis mortality: A population-based follow-up study. *Medicine*; **95**(1).
- Yew, W.W., Chang, K.C., Chan, D.P. 2018. Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity. *Antimicrob. Agents Chemother.* **62**(8) : e02637-17
- Zdanowicz, M.M. 2003. *Essentials of Pathophysiology for Pharmacy.* CRC Press LLC.
- Zimhony, O., Vilchèze, C., Arai, M., Welch, J. T., & Jacobs, W. R. 2007. Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli. *Antimicrobial agents and chemotherapy*, **51**(2)swqaw2xxaaaaaz, 752-754.

Lampiran 2. Hasil Uji Statistik

Correlations

		Bobot Badan	Pre AST
Bobot Badan	Pearson Correlation	1	,115
	Sig. (2-tailed)		,672
	N	16	16
Pre AST	Pearson Correlation	,115	1
	Sig. (2-tailed)	,672	
	N	16	16

Correlations

		Bobot Badan	Post AST
Bobot Badan	Pearson Correlation	1	-,161
	Sig. (2-tailed)		,552
	N	16	16
Post AST	Pearson Correlation	-,161	1
	Sig. (2-tailed)	,552	
	N	16	16

Correlations

		Bobot Badan	Pre ALT
Bobot Badan	Pearson Correlation	1	,145
	Sig. (2-tailed)		,592
	N	16	16
Pre ALT	Pearson Correlation	,145	1
	Sig. (2-tailed)	,592	
	N	16	16

Correlations

		Bobot Badan	Post ALT
Bobot Badan	Pearson Correlation	1	-,131
	Sig. (2-tailed)		,629
	N	16	16
Post ALT	Pearson Correlation	-,131	1
	Sig. (2-tailed)	,629	
	N	16	16

Correlations

		Albumin 1	Pre AST
Albumin 1	Pearson Correlation	1	-,427
	Sig. (2-tailed)		,099
	N	16	16
Pre AST	Pearson Correlation	-,427	1
	Sig. (2-tailed)	,099	
	N	16	16

Correlations

		Albumin 1	Post AST
Albumin 1	Pearson Correlation	1	-,203
	Sig. (2-tailed)		,451
	N	16	16
Post AST	Pearson Correlation	-,203	1
	Sig. (2-tailed)	,451	
	N	16	16

Correlations

		Albumin 1	Pre ALT
Albumin 1	Pearson Correlation	1	-,389
	Sig. (2-tailed)		,137
	N	16	16
Pre ALT	Pearson Correlation	-,389	1
	Sig. (2-tailed)	,137	
	N	16	16

Correlations

		Albumin 1	Post ALT
Albumin 1	Pearson Correlation	1	-,169
	Sig. (2-tailed)		,532
	N	16	16
Post ALT	Pearson Correlation	-,169	1
	Sig. (2-tailed)	,532	
	N	16	16

Correlations

		Albumin 1	Pre AST
Albumin 1	Pearson Correlation	1	-,393
	Sig. (2-tailed)		,132
	N	16	16
Pre AST	Pearson Correlation	-,393	1
	Sig. (2-tailed)	,132	
	N	16	16

Correlations

		Albumin 1	Post AST
Albumin 1	Pearson Correlation	1	-,874**
	Sig. (2-tailed)		,000
	N	16	16
Post AST	Pearson Correlation	-,874**	1
	Sig. (2-tailed)	,000	
	N	16	16

** . Correlation is significant at the 0.01 level (2-tailed).

Correlations

		Albumin 1	Pre ALT
Albumin 1	Pearson Correlation	1	-,513*
	Sig. (2-tailed)		,042
	N	16	16
Pre ALT	Pearson Correlation	-,513*	1
	Sig. (2-tailed)	,042	
	N	16	16

* . Correlation is significant at the 0.05 level (2-tailed).

Correlations

		Albumin 1	Post ALT
Albumin 1	Pearson Correlation	1	-,785**
	Sig. (2-tailed)		,000
	N	16	16
Post ALT	Pearson Correlation	-,785**	1
	Sig. (2-tailed)	,000	
	N	16	16

** . Correlation is significant at the 0.01 level (2-tailed).

Lampiran 3. Kode Etik


 KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
 Contact Person: dr. Aguslaim Bukhari, MMed,PhD, SpCK, TELP. 081241850858, 0411 5780033, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK
 Nomor : 738/UN4.6.4.5.31/PP36/2020

Tanggal: 11 Nopember 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20080371		No Sponsor Protokol	
Peneliti Utama	Sriyanty Sadsyam,S.Farm		Sponsor	
Judul Peneliti	Evaluasi Pengaruh Kadar Albumin Darah sebagai Faktor Resiko Hepatotoksik Akibat Penggunaan OAT-KDT di Balai Besar Kesehatan Paru Masyarakat Makassar			
No Versi Protokol	1	Tanggal Versi	11 Agustus 2020	
No Versi PSP	1	Tanggal Versi	11 Agustus 2020	
Tempat Penelitian	Balai Besar Kesehatan Paru Masyarakat Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku	11 Nopember 2020 sampai 11 Nopember 2021 Frekuensi review lanjutan	
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan		
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan		

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 4. Surat Izin Penelitian



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN
FAKULTAS FARMASI
 Alamat Jalan Perintis kemerdekaan Km.10, Makassar 90245
 Telepon (0411) 588556, Faksimili (0411) 590663
 Laman: farmasi.unhas.ac.id

Nomor : 419/UN4.17/PT.01.04/2020 5 Februari 2020
 Hal : Permohonan Izin Penelitian

Yth. Kepala Balai Besar Kesehatan Paru Masyarakat
 di
 Makassar

Dengan hormat, sehubungan dengan pelaksanaan penelitian mahasiswa Fakultas Farmasi di bawah ini :

Nama Mahasiswa	: Sriyanty Sadsyam
Nomor Pokok	: N012171025
Program Studi	: S2 Farmasi
Konsentrasi	: Farmasi Klinik

judul "Evaluasi Pengaruh Kadar Albumin Darah sebagai Faktor Resiko Hepatotoksik Akibat Penggunaan OAT KDT dan Tablet Lepas di Balai Besar Kesehatan Paru Masyarakat Makassar".

Kami mohon bantuannya, kiranya mahasiswa tersebut di atas dapat diizinkan melaksanakan penelitian di Balai Besar Kesehatan Paru Masyarakat Makassar. Adapun persyaratan teknis dan administrasi akan dipenuhi sesuai dengan ketentuan dan peraturan yang berlaku di Balai Besar Kesehatan Paru Masyarakat Makassar.

Demikian permohonan ini diajukan, atas perhatian dan bantuannya disampaikan terima kasih.



Subehan, M.Pharm.Sc., Ph.D., Apt. 
 NIP. 109509252001121002

Tembusan:

1. Wakil Dekan Bid. Akademik, Riset dan Inovasi
2. Ketua Gugus Penjamin Mutu
3. Ketua Prodi S2 Farmasi
4. Kabag. Tata Usaha

Anip

